论文部分内容阅读
目的:探讨循环微小RNA 152(miR-152)对前列腺癌生化复发早期预测的价值。方法:收集将要进行前列腺癌手术的患者66例(生化复发组:35例,术后2年内生化复发;未生化复发组:31例,术后2年内未生化复发),另择年龄相匹配的31例健康男性作为健康对照组。用qRT-PCR法检测前列腺癌患者和健康对照组的循环miR-152表达水平。应用ROC曲线分析循环miR-152对前列腺癌早期生化复发的诊断价值。分析复发组循环miR-152表达水平与临床病理参数(年龄、术前PSA水平、Gleason积分、临床分期、骨转移)之间的相关性。结果:循环miR-152在前列腺癌术后患者(未生化复发及生化复发)与健康对照组的表达差异有统计学意义(t=-5.212,P=0.001)。前列腺癌术后生化复发组患者循环miR-152的表达量较未生化复发组患者低,差异有统计学意义(t=-5.727,P=0.001)。循环miR-152对前列腺癌术后生化复发早期预测的ROC曲线下面积(AUC)为0.906(95%CI,0.809~0.964),灵敏度和特异度分别为91.4%、80.6%。循环miR-152表达水平与Gleason积分、临床分期、有无生化复发和骨转移相关(P均<0.05);随着Gleason积分、临床分期的增加,循环miR-152的表达水平下降。但miR-152表达量与患者年龄、术前PSA无关(P均>0.05)。结论:循环miR-152表达水平在前列腺癌术后生化复发患者中显著降低,可能成为前列腺癌生化复发早期预测的分子标志物。
Objective: To investigate the value of circulating microRNA 152 (miR-152) in early prediction of biochemical recurrence of prostate cancer. Methods: Sixty-six patients (biochemical recurrence group: 35 patients, biochemical recurrence within 2 years after operation), 31 patients without biochemical recurrence, and no biochemical recurrence within 2 years after operation were enrolled in this study. The age-matched patients 31 healthy males served as healthy control group. Circulating miR-152 expression was detected by qRT-PCR in prostate cancer patients and healthy controls. Using ROC Curves to Diagnose Early Biochemical Recurrence of Prostate Cancer by Cyclic miR-152. The correlation between circulating miR-152 expression level and clinical pathological parameters (age, preoperative PSA level, Gleason score, clinical stage and bone metastasis) was analyzed. Results: There was a significant difference in the expression of circulating miR-152 in patients with prostate cancer (no biochemical recurrence and biochemical recurrence) and healthy controls (t = -5.212, P = 0.001). The expression of circulating miR-152 in postoperative biochemical recurrence group was lower than that in non-biochemical recurrence group, the difference was statistically significant (t = -5.727, P = 0.001). The area under the ROC curve (AUC) of circulating miR-152 in the early prediction of postoperative biochemical recurrence of prostate cancer was 0.906 (95% CI, 0.809-0.964). The sensitivity and specificity were 91.4% and 80.6% respectively. The expression of circulating miR-152 was correlated with Gleason score, clinical stage, biochemical recurrence and bone metastasis (all P <0.05). With the increase of Gleason score and clinical stage, the expression level of circulating miR-152 decreased. However, the expression of miR-152 was not associated with the age of the patients or the preoperative PSA (all P> 0.05). Conclusion: The expression of circulating miR-152 is significantly decreased in patients with biochemical recurrence of prostate cancer and may be a molecular marker for early prediction of biochemical recurrence of prostate cancer.